{"release":"wpf-research-journeys","version":"1.0.0","checkedOn":"2026-11-13","verificationLabel":"AI-assisted source verification","humanReview":"none recorded","journey":{"slug":"semaglutide","name":"Semaglutide","aliases":["Wegovy","Ozempic","Rybelsus"],"profileUrl":"/directory/semaglutide","summary":"Two registered trials that compare semaglutide, one against placebo and one head to head with tirzepatide, with their exact results and the U.S. decision for the Wegovy product.","studies":[{"registryId":"NCT03548935","title":"STEP 1: semaglutide 2.4 mg once weekly in adults with overweight or obesity","status":"Completed","phase":"Phase 3","resultsPosted":true,"resultsFirstPosted":"2021-08-11"},{"registryId":"NCT05822830","title":"SURMOUNT-5: tirzepatide versus semaglutide in adults with obesity","status":"Completed","phase":"Phase 3","resultsPosted":true,"resultsFirstPosted":"2025-11-26"}],"results":[{"resultId":"step-1-weight-68w","trial":"STEP 1 (double-blind)","comparison":"Semaglutide 2.4 mg vs placebo, plus lifestyle intervention","registryId":"NCT03548935","pmid":"33567185","doi":"10.1056/NEJMoa2032183","population":"1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes","comparator":"Placebo plus lifestyle intervention (2:1 randomization)","endpoint":"Percent change in body weight and weight reduction of at least 5% (coprimary)","timePoint":"68 weeks","result":"-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points","uncertainty":"Difference 95% CI -13.4 to -11.5","locator":"Flagship Weight Management 1.3.0: open \"Verify this result\" on the result for the table, figure or text location of each displayed number.","locatorStatus":"matched","limits":["Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is \"regardless of treatment discontinuation or rescue interventions\"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means."],"source":"flagship_release","versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=step-1-weight-68w","citation":"STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. Primary source: https://doi.org/10.1056/NEJMoa2032183 (PMID 33567185; NCT03548935). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.3.0, result step-1-weight-68w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=step-1-weight-68w. Page: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w.","verifyUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w"},{"resultId":"surmount-5-weight-72w","trial":"SURMOUNT-5 (phase 3b, open-label)","comparison":"Tirzepatide vs semaglutide","registryId":"NCT05822830","pmid":"40353578","doi":"10.1056/NEJMoa2416394","population":"751 adults with obesity, without type 2 diabetes","comparator":"Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly","endpoint":"Percent change in weight from baseline to week 72","timePoint":"72 weeks","result":"-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)","uncertainty":"95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)","locator":"Flagship Weight Management 1.3.0: open \"Verify this result\" on the result for the table, figure or text location of each displayed number.","locatorStatus":"matched","limits":["Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label."],"source":"flagship_release","versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w","citation":"SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. Primary source: https://doi.org/10.1056/NEJMoa2416394 (PMID 40353578; NCT05822830). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.3.0, result surmount-5-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w. Page: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w.","verifyUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"}],"decisions":[{"id":"fda-wegovy-nda215256","jurisdiction":"United States","regulator":"FDA","product":"WEGOVY (semaglutide) injection, NDA 215256","indication":"Chronic weight management. FDA's Drugs@FDA record lists the original approval as a new indication submitted as a distinct NDA. The current indications are in the linked prescribing information; WPF's automated check could not retrieve the June 2026 label from FDA (HTTP 404 to a non-browser request), so they are not restated here.","actionType":"New drug application approval (original), with later labeling supplements","decisionDate":"2021-06-04","dateChecked":"2026-11-13","sourceTitle":"openFDA Drugs@FDA record for NDA215256 (submission ORIG-1, status AP, 2021-06-04; latest efficacy supplement 2026-03-19)","sourceUrl":"https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA215256&limit=1","readerUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","limits":"Other semaglutide products (Ozempic, Rybelsus) are separate applications with their own decisions and are not covered by this record. Approval is regulatory context, not evidence that a trial result applies to a given person."}],"film":{"title":"Semaglutide: one molecule, different medicines","url":"/films/metabolic/06-semaglutide"},"filmNote":"","noRecordJurisdictions":["European Union (other than the profile's EPAR link)","United Kingdom","Canada","Australia","Japan","China"]},"sha256":"11eb688bae0b1c0d43e1b4d7f2ef248f0d2c5d9093c24c4b011c0f30569ef35c"}